The Role of Intravenous Albumin Replacement During Abdominal Paracentesis in Patients With Malignancy Related Ascites

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-06-30

Study Completion Date

2017-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Aims: To compare the rates of hypotension in patients with malignancy-related ascites undergoing abdominal paracentesis with and without prophylactic intravenous albumin infusion

Methodology: Patients with symptomatic ascites secondary to underlying malignancy admitted to medical oncology inpatient service who require abdominal paracentesis will be enrolled. Patients with known portal hypertension based on SAAG (\>11.1 mmol/L) will be excluded. Eligible patients are randomized 1:1 to two groups. During drainage of ascites fluid, one group will receive intravenous albumin infusion (50 ml/Litre of ascitic fluid drained), whereas the other group will not receive intravenous albumin infusion. Baseline parameters along with routine 4 hourly monitoring of blood pressure will be done. Episodes of hypotension (fall in SBP \> 20 mmHg) will be compared between these two groups and significance tested using the chi-square test.

Clinical significance: Ascites often occurs in the setting of advanced malignancy and drainage of ascites has been proven to provide symptomatic relief in this patient population with relatively short life expectancy. The use of intravenous albumin infusion is loosely extrapolated from studies in patients with liver cirrhosis undergoing abdominal paracentesis. To date, there have been no standard guidelines to guide practice and no studies looking at the use of intravenous albumin in this population. As the mechanisms of ascites are different in different malignancies, the indication of intravenous albumin is uncertain and perhaps unnecessary in this setting. We hope to understand more about the rates of hypotension during abdominal paracentesis in this population and to generate systematic data to guide clinical practice in this area.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Continuous Passive Paracentesis for Intra-abdominal Hypertension

NCT04322201

Ascites Hepatic Cirrhosis, Liver Hypertension, Intraabdominal +2 more

UNKNOWN NA

Albumin 4 gr/L vs 8 gr/L in the Prevention of Post-Paracentesis Circulatory Dysfunction

NCT00428506

Tense Ascites in Cirrhosis

UNKNOWN PHASE2

Formation and Severity of Pressure Ulcers Associated With 4% Albumin vs. 0.9% Sodium Chloride

NCT00228657

Pressure Ulcer, Area Pressure Ulcer, Grade Albumin Level +2 more

COMPLETED PHASE1/PHASE2

Strong Albumin Solutions in Patients With Septic Shock

NCT05208242

Sepsis Septic Shock Shock, Toxic

COMPLETED PHASE2/PHASE3

Preoperative Ascites Drainage Versus Standard Care for Patients With Advanced Ovarian Cancer

NCT02742428

Ascites Ovarian Epithelial Cancer Malnutrition

SUSPENDED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

General Introduction:

Therapeutic paracentesis is the first line of treatment for patients with symptomatic malignant ascites. The practice of intravenous albumin infusion during abdominal paracentesis comes from evidence in patients with liver cirrhosis. A meta-analysis of seventeen randomised trials evaluating patients receiving albumin versus alternative treatment during large volume paracentesis found that albumin reduced the incidence of post-paracentesis circulatory dysfunction, hyponatraemia and mortality (Bernardi M, 2012). The mechanisms of ascites in patients with cirrhosis are driven by portal hypertension. Portal hypertension brings about systemic vasodilation and hyperdynamic circulation that eventually contribute to functional and biochemical changes leading to ascites (Gines. P, 1997).

In contrast, cause of ascites in patients with malignancies is usually multi-factorial. It occurs commonly in several tumours including malignancies of ovary, breast, colon, lung, pancreas and liver. In each of these cancer types, the mechanisms leading to malignancy-related ascites may be different. Peritoneal carcinomatosis is a major cause of malignancy-related ascites. Other causes include massive liver metastasis causing portal hypertension, chronic hypoalbuminaemia, hepatocellular carcinoma, chylous ascites from lymphoma and Budd-Chiari syndrome due to occlusion of hepatic veins (Runyon BA, 1988).

In patients with cancer, aside from those who develop ascites as a result of portal hypertension, the benefit of intravenous albumin infusion with large volume paracentesis is uncertain, if at all present. Locally, the current clinical practice is for infusion of intravenous albumin during abdominal paracentesis in patients with malignancy-related ascites regardless of cause. The drawbacks of such an approach include exposing patients to risk of anaphylaxis and increased financial costs (50 ml of 20% Albumin costs $42).

Granted that the potential harms of albumin infusion are rare, the burden of proof to show that an intervention works is held by those who introduce it. To date, there have been no studies specifically examining the role of intravenous albumin infusion in this population. In the setting of advanced cancer where life expectancy is limited, the most clinically relevant benefit of albumin infusion would be to reduce the rates of post-paracentesis circulatory dysfunction. Through a pilot study, we hope to evaluate the effectiveness of IV albumin in reducing rates of hypotension, thereby guiding clinical practice in this area.

Rationale and justification for the Study:

Hypothesis: Intravenous albumin infusion during abdominal paracentesis does not prevent hypotension in patients with malignancy-related ascites without portal hypertension.

Rationale for the Study Purpose:

Three significant outcomes have been proven for the use of intravenous albumin in large volume paracentesis in patients with cirrhosis. These are prevention of hypotension, prevention of hyponatraemia and survival benefit. Ascites in the setting of patients with malignancy usually occurs in advanced stage, of which the most meaningful outcome would be that of prevention of hypotension. At present, the current clinical practice locally is extrapolated from studies in patients with cirrhosis, and some physicians would opt to administer IV albumin with every litre of ascitic fluid drained. We propose a study to compare the rates of hypotension in patients who received IV albumin and those who do not. In this study, we will randomise patients with a known history of cancer who are admitted for symptomatic ascites to two groups. Both groups of patients will undergo insertion of abdominal drain for symptomatic relief. Group 1 will receive intravenous albumin and Group 2 will not.

Rationale for Doses Selected:

In Group 1, 50 ml of 20% intravenous albumin will be given for every litre of ascitic fluid drained as this is the current local preparation and practice.

Rationale for Study Population:

Replacement of intravenous albumin has been established in patients with ascites drainage for patients with liver cirrhosis. It has not been shown to benefit patients with malignancy.

Rationale for Study Design:

There have been no previous studies in patients of this population. This is a prospective pilot randomised study in order to compare the rates of hypotension between the two groups.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ascites Hypotension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Receives IV albumin infusion

IV albumin 20% 50 mL for every 1L of ascitic fluid drained

Group Type EXPERIMENTAL

Receives IV albumin infusion

Intervention Type PROCEDURE

IV albumin 20% 50 mL for every 1L of ascitic fluid drained. Blood pressure and heart rate are recorded every four hours in both groups in the first 48 hours.

If hypotension occurs (defined as fall in systolic blood pressure of \> 20 mmHg from baseline) during drainage, drain is clamped and the patient will be clinically evaluated for cause of hypotension. If no other causes of hypotension are found and patient remains asymptomatic, repeat blood pressure measurement in 30 minutes. If blood pressure maintains \> 90/50 mmHg after 30 minutes and patient is asymptomatic, continue drainage and patient stays in the study. If patient remains hypotensive (BP \< 90/50) or develops symptomatic hypotension, then the patient will be taken off study and the hypotension managed as clinically indicated.

Do not receive IV albumin infusion

No IV albumin infusion

Group Type PLACEBO_COMPARATOR

Do not receive IV albumin infusion

Intervention Type BIOLOGICAL

No IV albumin infusion. Blood pressure and heart rate are recorded every four hours in both groups in the first 48 hours.

If hypotension occurs (defined as fall in systolic blood pressure of \> 20 mmHg from baseline) during drainage, drain is clamped and the patient will be clinically evaluated for cause of hypotension. If no other causes of hypotension are found and patient remains asymptomatic, repeat blood pressure measurement in 30 minutes. If blood pressure maintains \> 90/50 mmHg after 30 minutes and patient is asymptomatic, continue drainage and patient stays in the study. If patient remains hypotensive (BP \< 90/50) or develops symptomatic hypotension, then the patient will be taken off study and the hypotension managed as clinically indicated.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Receives IV albumin infusion

IV albumin 20% 50 mL for every 1L of ascitic fluid drained. Blood pressure and heart rate are recorded every four hours in both groups in the first 48 hours.

If hypotension occurs (defined as fall in systolic blood pressure of \> 20 mmHg from baseline) during drainage, drain is clamped and the patient will be clinically evaluated for cause of hypotension. If no other causes of hypotension are found and patient remains asymptomatic, repeat blood pressure measurement in 30 minutes. If blood pressure maintains \> 90/50 mmHg after 30 minutes and patient is asymptomatic, continue drainage and patient stays in the study. If patient remains hypotensive (BP \< 90/50) or develops symptomatic hypotension, then the patient will be taken off study and the hypotension managed as clinically indicated.

Intervention Type PROCEDURE

Do not receive IV albumin infusion

No IV albumin infusion. Blood pressure and heart rate are recorded every four hours in both groups in the first 48 hours.

If hypotension occurs (defined as fall in systolic blood pressure of \> 20 mmHg from baseline) during drainage, drain is clamped and the patient will be clinically evaluated for cause of hypotension. If no other causes of hypotension are found and patient remains asymptomatic, repeat blood pressure measurement in 30 minutes. If blood pressure maintains \> 90/50 mmHg after 30 minutes and patient is asymptomatic, continue drainage and patient stays in the study. If patient remains hypotensive (BP \< 90/50) or develops symptomatic hypotension, then the patient will be taken off study and the hypotension managed as clinically indicated.

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age more than 21 years old
* Inpatients admitted to medical oncology service with symptomatic ascites and who are scheduled for abdominal paracentesis
* Known underlying malignancy
* Blood pressure before abdominal paracentesis more than 90/50 mmHg

Exclusion Criteria

* Patients with known portal hypertension, defined by serum albumin: ascites gradient (SAAG) more than 11.1 mmol/L, based on previous results in last 1 year
* Patients with a known history of hypotension when getting paracentesis
* Pregnant women

Minimum Eligible Age

21 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No